Physician
Oncology
Dr. Philip M. Arlen, MD
|
|
Give Review
Doctor Philip M. Arlen, MD practices Oncology. He researched medicine at Medical College of Georgia School of Medicine. Philip M. Arlen, MD is a published doctor. He has 98 papers published. The most current publication "Multiple myeloma after treatment of essential thrombocythemia."
Publications
- Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer.
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
- Recent advances revolutionize treatment of metastatic prostate cancer.
- Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
- Nanocytology vs. Immunohistochemistry of Intestinal Colonocytes to Assess the Risk of Colon Cancer based on Field Cancerization - A Preliminary Report.
- A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer.
- A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal maligna...
- Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
- Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC.
- A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
- Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
- Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
- Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an ...
- Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
- Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
- Paradigm shifts in cancer vaccine therapy.
- Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
- A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
- Clinical safety of a viral vector based prostate cancer vaccine strategy.
- Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
- Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
- Cancer vaccines: moving beyond current paradigms.
- Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
- Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review...
- Combining Vaccines with Conventional Therapies for Cancer.
- Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
- Immunotherapy for prostate cancer: what's the future?
- A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-02...
- A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or...
- Therapeutic vaccines for prostate cancer.
- A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
- A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
- Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
- Costimulatory molecules as adjuvants for immunotherapy.
- Pox viral vaccine approaches.
- A phase II study of perifosine in androgen independent prostate cancer.
- Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
- Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
- Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
- Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
- Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colon...
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
- Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
- A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
- Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
- National Cancer Institute intramural approach to advanced prostate cancer.
- Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
- Promising novel immunotherapies and combinations for prostate cancer.
- PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
- Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
- Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
- New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
- Current perspectives in prostate cancer vaccines.
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
- Cancer vaccines: current directions and perspectives in prostate cancer.
- Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
- Therapeutic prostate cancer vaccines: a review of the latest developments.
- Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
- Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
- Role of vaccine therapy in cancer: biology and practice.
- Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
- PSA-based vaccines for the treatment of prostate cancer.
- Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only t...
- Abiraterone. Cougar Biotechnology.
- TRICOM vector based cancer vaccines.
- Therapeutic vaccines for prostate cancer: a review of clinical data.
- Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
- Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
- A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
- Multiple myeloma after treatment of essential thrombocythemia.
- Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylat...
- A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
- Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing aden...
- Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox ...
- The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
- Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
- The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with m...
- The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specif...
- A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
- Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
- Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
- Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
- A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
- A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
- A retrospective study of the time to clinical endpoints for advanced prostate cancer.
- Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
- Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques.
- Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
- The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.
Schools
Medical College of Georgia
Ga Bapt Health Care Sys
Emory University Mc
NciNih
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Emory University -
Medical College of Georgia School of Medicine
Helpful Reviews
Similar Doctors
|
|
Louis M. Staudt |
|
|
Ramaprasad Srinivasan, MB
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kieron M. Dunleavy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haobin Chen, MD |
|
|
Dr. Joanne Zujewski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norman Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrian M. Senderowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alain Thibault, MD |
|
|
Dr. Victor M. Priego, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Hourigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan E. Bates, MD |
|
|
Dr. Robert J. Lechleider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel Broder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Giuseppe Giaccone
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Richard J. Hodes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|